Previous 10 | Next 10 |
2024-05-15 09:25:53 ET Gainers: SINTX Technologies ( SINT ) +186% . Faraday Future Intelligent Electric ( FFIE ) +82% . Edible Garden AG EDBL +82% after Q1 earnings release . AERWINS Technologies ( AWIN ) +33% . Greenwave Technology Solu...
2024-05-14 16:02:12 ET Summary Humacyte's stock price has recently been on an impressive bull run, jumping from $4.50 to $6.50 after management announced Q1 2024 earnings. The company's market cap valuation is currently around $765 million - I believe this could rise >$1bn if t...
2024-05-14 07:28:38 ET More on Humacyte Humacyte, Inc. (HUMA) Q1 2024 Earnings Call Transcript Humacyte, Inc. (HUMA) Q4 2023 Earnings Call Transcript Humacyte GAAP EPS of -$0.24 in-line Humacyte stock dips after pricing stock offering to raise $40.2M ...
DURHAM, N.C., May 13, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, today announced that Laura Niklason, M.D., Ph.D., Founder, President, and Chief Ex...
2024-05-12 00:59:05 ET Humacyte, Inc. (HUMA) Q1 2024 Earnings Conference Call May 10, 2024 08:00 AM ET Company Participants Tom Johnson - Investor Relations, LifeSci Advisors Laura Niklason - Founder, President, Chief Executive Officer Dale Sander - Chief Financi...
2024-05-10 11:54:17 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Humacyte (NASDAQ: HUMA ) just reported results for the first quarter of 2024. Humacyte reported earnings per share of -29 cents. This was below the analyst estimate for EP...
2024-05-10 07:02:08 ET More on Humacyte Humacyte, Inc. (HUMA) Q4 2023 Earnings Call Transcript Humacyte GAAP EPS of -$0.24 in-line Humacyte stock dips after pricing stock offering to raise $40.2M Seeking Alpha’s Quant Rating on Humacyte Histori...
Jet.AI Inc. (JTAI) is expected to report for Q1 2024 Forian Inc. (FORA) is expected to report $-0.02 for Q1 2024 Square Enix Holdings Co. Ltd (SQNXF) is expected to report for Q4 2024 Qutoutiao Inc. (QTT) is expected to report for Q4 2023 Molecular Partners AG (MOLN) is expected t...
-Biologics License Application (BLA) for HAV™ Accepted by FDA- -BLA Granted Priority Review for Vascular Trauma Indication; PDUFA date set for August 10, 2024- -Raised approximately $43 million in net proceeds from public offering of common stock- -Conference call...
2024-05-09 11:39:53 ET More on Humacyte Humacyte, Inc. (HUMA) Q4 2023 Earnings Call Transcript Humacyte GAAP EPS of -$0.24 in-line Humacyte stock dips after pricing stock offering to raise $40.2M Seeking Alpha’s Quant Rating on Humacyte Histori...
News, Short Squeeze, Breakout and More Instantly...
DURHAM, N.C., July 16, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, announced the addition of pharmaceutical industry veteran Dr. John P. Bamforth and di...
Pluristyx, a leading provider of tools, technologies, and services for the development of cellular therapies, is pleased to announce a license agreement with Humacyte, Inc., a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercia...
2024-07-01 10:28:20 ET Humacyte Inc (NASDAQ: HUMA) opened close to 25% up on Monday after the Food & Drug Administration granted its ATEV a special advanced-therapy designation. Shares of the biotech firm are still down some 30% versus their year-to-date high. Why does it ma...